Tisdag 26 November | 07:40:34 Europe / Stockholm
Svenska | English

Surgical Science Sweden AB (publ)

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2026-02-19 07:30 Bokslutskommuniké 2025
2025-11-13 07:30 Kvartalsrapport 2025-Q3
2025-08-21 07:30 Kvartalsrapport 2025-Q2
2025-05-14 07:30 Kvartalsrapport 2025-Q1
2025-02-19 07:30 Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning SUS 0.00 SEK
2024-05-16 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning SUS 0.00 SEK
2023-05-17 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-13 - X-dag ordinarie utdelning SUS 0.00 SEK
2022-05-12 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-16 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-08-16 - Extra Bolagsstämma 2021
2021-05-14 - X-dag ordinarie utdelning SUS 0.00 SEK
2021-05-12 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-25 - Split SUS 1:5
2020-05-07 - X-dag ordinarie utdelning SUS 0.00 SEK
2020-05-06 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-07-17 - Extra Bolagsstämma 2019
2019-05-10 - X-dag ordinarie utdelning SUS 0.00 SEK
2019-05-09 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-11-21 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-23 - X-dag ordinarie utdelning SUS 0.00 SEK
2018-05-22 - Årsstämma
2018-05-22 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Surgical Science Sweden är verksamt inom medicinteknik. Bolaget utvecklar VR-simulatorer inom kirurgin. Simulatorerna består både hård- och mjukvara som används i träning och personlig utveckling hos kirurger. Hårdvaran simulerar diverse kirurgiska ingrepp, med främst användning inom titthålskirurgi samt endoskopi. Visionen är att stärka kompetensen inom kirurgin samt skapa förutsättningar för bättre behandlingar. Bolaget har sitt huvudkontor i Göteborg.
CEO Gisli Hennermark will leave Surgical Science in March 2025
2024-03-12 08:29:00

Today Gisli Hennermark, CEO of Surgical Science Sweden AB (publ), has informed the board that he intends to leave his position. The board now initiates the work of finding a successor to Gisli. That process will be led by the chairman of the board, Roland Bengtsson. Gisli remains as CEO until the board appoints a new CEO and will be an advisor to the new CEO until March, 2025.

"Surgical Science has had nine fantastic years with Gisli, where he has far exceeded all expectations you can have of a CEO. We have had a collaboration that has been incredibly successful and over this time has generated great value for all shareholders. I regret that Gisli has decided to leave but I also know that the company is standing strong and that the existing team is driving the company forward with full force. We continue our journey where our financial goals for 2026 is only a step on the way. I am grateful that Gisli's strong commitment and care for the business means that he remains in the company for another year," says Roland Bengtsson, chairman of the board of Surgical Science.

"My almost nine years as CEO of Surgical Science has been the dream job of my life. I am extremely proud of all my colleagues and how we contribute to better safety for patients worldwide through simulation. Having been able to make this growth journey with my team and the board from a small cutting-edge technology company in Gothenburg to a world-leading group has been a privilege. I know I will miss everything that I love about Surgical Science but it is a good time to hand over the responsibility for its continued growth to someone else. It is almost three years since the acquisition of Simbionix and the integration has exceeded all expectations. The company is now ready for new chapters in its development," says Surgical Science’s CEO Gisli Hennermark.

Gothenburg, Sweden, March 12, 2024
Surgical Science Sweden AB (publ)

This press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 260 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Carnegie Investment Bank AB (publ).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-12 08:29 CET.

Attachments

CEO Gisli Hennermark will leave Surgical Science in March 2025

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden